CURRICULUM VITAE

유태현

연세대학교 세브란스 병원

[학력]

1995년	연세대학교 의과대학 졸업
2005년	연세대학교 내과학 박사

[경력]

2008년	연세대학교 신장내과 조교수
2018년-	연세대학교 신장내과 교수

[관심분야]

당뇨병성 신증, 급성 신손상

[논문]

- 1. Park, C. H., et al. (2024). "Nocturnal systolic blood pressure dipping and progression of chronic kidney disease." Hypertens Res 47(1): 215-224.
- 2. Kim, C. H., et al. (2023). "Soluble receptors for advanced glycation end-products prevent unilateral ureteral obstruction-induced renal fibrosis." Front Pharmacol 14: 1172269.
- 3. Jhee, J. H., et al. (2023). "Short-term Blood Pressure Variability and Incident CKD in Patients With Hypertension: Findings From the Cardiovascular and Metabolic Disease Etiology Research Center-High Risk (CMERC-HI) Study." Am J Kidney Dis 81(4): 384-393.e381.
- 4. Lee, J. Y., et al. (2022). "Association of blood pressure with cardiovascular outcome and mortality: results from the KNOW-CKD study." Nephrol Dial Transplant 37(9): 1722-1730.
- 5. Kim, S., et al. (2021). "Exosome-based delivery of super-repressor $I\kappa B\alpha$ ameliorates kidney ischemiareperfusion injury." Kidney Int 100(3): 570-584.





Dyslipidemia in chronic kidney disease

Tae-Hyun Yoo

Department of Internal Medicine, Yonsei University College of Medicine, Seoul

As the average age increase, hypertension and diabetes has been gradually increasing and the prevalence of chronic kidney disease patients is rapidly increasing. Hypertension, along with diabetes, is a representative complication of chronic kidney disease (CKD) and the increases in the risk of cardiovascular disease, thereby increasing mortality. In addition, with continued decline in renal function, there is a high possibility of progression to end stage kidney failure requiring dialysis or transplantation. Dyslipidemia is known to be the common cause of CVD in diabetes and hypertension. In CKD, dyslipidemia is closely related to high risk in CVD and mortality. Thoroughly, controlling lipid profiles has been found to be a very important treatment policy not only in the general population but also in patients with diabetes and hypertension, so it is important to control dyslipidemia and set appropriate cholesterol targets. However, there was controversy over setting cholesterol targets in CKD population. Therefore, in this session, the prognostic roles and optimal lipid targets in CKD will be presented.